Contineum Therapeutics (NASDAQ:CTNM) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Contineum Therapeutics (NASDAQ:CTNM) from a sell rating to a hold rating in a research note issued to investors on Saturday.

Other analysts have also issued research reports about the company. Robert W. Baird reduced their target price on Contineum Therapeutics from $16.00 to $14.00 and set an “outperform” rating for the company in a report on Monday, November 24th. Royal Bank Of Canada dropped their price target on Contineum Therapeutics from $25.00 to $22.00 and set an “outperform” rating on the stock in a research report on Friday, November 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Contineum Therapeutics in a research report on Wednesday, January 21st. Morgan Stanley reiterated an “equal weight” rating and issued a $14.00 target price (down previously from $23.00) on shares of Contineum Therapeutics in a report on Thursday, January 8th. Finally, Leerink Partners assumed coverage on shares of Contineum Therapeutics in a research report on Thursday, November 13th. They issued an “outperform” rating and a $22.00 price target for the company. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $19.00.

Contineum Therapeutics Stock Performance

Shares of NASDAQ:CTNM opened at $14.44 on Friday. The firm has a 50 day simple moving average of $12.52 and a 200 day simple moving average of $11.27. Contineum Therapeutics has a 52 week low of $3.35 and a 52 week high of $16.01. The company has a market cap of $421.36 million, a PE ratio of -6.42 and a beta of 1.17.

Hedge Funds Weigh In On Contineum Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its stake in Contineum Therapeutics by 1.3% in the fourth quarter. Geode Capital Management LLC now owns 213,869 shares of the company’s stock valued at $2,446,000 after acquiring an additional 2,819 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in shares of Contineum Therapeutics during the 4th quarter valued at $43,000. Strs Ohio acquired a new stake in shares of Contineum Therapeutics in the 1st quarter valued at $27,000. Bank of America Corp DE lifted its stake in shares of Contineum Therapeutics by 500.0% in the 3rd quarter. Bank of America Corp DE now owns 7,236 shares of the company’s stock valued at $85,000 after purchasing an additional 6,030 shares during the last quarter. Finally, Qube Research & Technologies Ltd bought a new stake in Contineum Therapeutics in the second quarter worth $43,000.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.